Cargando…
A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials
We propose an “efficacy-to-effectiveness” (E2E) clinical trial design, in which an effectiveness trial would commence seamlessly upon completion of the efficacy trial. Efficacy trials use inclusion/exclusion criteria to produce relatively homogeneous samples of participants with the target condition...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904553/ https://www.ncbi.nlm.nih.gov/pubmed/24060819 http://dx.doi.org/10.1038/clpt.2013.177 |
_version_ | 1782301221162319872 |
---|---|
author | Selker, H P Oye, K A Eichler, H-G Stockbridge, N L Mehta, C R Kaitin, K I McElwee, N E Honig, P K Erban, J K D'Agostino, R B |
author_facet | Selker, H P Oye, K A Eichler, H-G Stockbridge, N L Mehta, C R Kaitin, K I McElwee, N E Honig, P K Erban, J K D'Agostino, R B |
author_sort | Selker, H P |
collection | PubMed |
description | We propose an “efficacy-to-effectiveness” (E2E) clinical trial design, in which an effectiveness trial would commence seamlessly upon completion of the efficacy trial. Efficacy trials use inclusion/exclusion criteria to produce relatively homogeneous samples of participants with the target condition, conducted in settings that foster adherence to rigorous clinical protocols. Effectiveness trials use inclusion/exclusion criteria that generate heterogeneous samples that are more similar to the general patient spectrum, conducted in more varied settings, with protocols that approximate typical clinical care. In E2E trials, results from the efficacy trial component would be used to design the effectiveness trial component, to confirm and/or discern associations between clinical characteristics and treatment effects in typical care, and potentially to test new hypotheses. An E2E approach may improve the evidentiary basis for selecting treatments, expand understanding of the effectiveness of treatments in subgroups with particular clinical features, and foster incorporation of effectiveness information into regulatory processes. |
format | Online Article Text |
id | pubmed-3904553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-39045532014-02-01 A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials Selker, H P Oye, K A Eichler, H-G Stockbridge, N L Mehta, C R Kaitin, K I McElwee, N E Honig, P K Erban, J K D'Agostino, R B Clin Pharmacol Ther State of the Art We propose an “efficacy-to-effectiveness” (E2E) clinical trial design, in which an effectiveness trial would commence seamlessly upon completion of the efficacy trial. Efficacy trials use inclusion/exclusion criteria to produce relatively homogeneous samples of participants with the target condition, conducted in settings that foster adherence to rigorous clinical protocols. Effectiveness trials use inclusion/exclusion criteria that generate heterogeneous samples that are more similar to the general patient spectrum, conducted in more varied settings, with protocols that approximate typical clinical care. In E2E trials, results from the efficacy trial component would be used to design the effectiveness trial component, to confirm and/or discern associations between clinical characteristics and treatment effects in typical care, and potentially to test new hypotheses. An E2E approach may improve the evidentiary basis for selecting treatments, expand understanding of the effectiveness of treatments in subgroups with particular clinical features, and foster incorporation of effectiveness information into regulatory processes. Nature Publishing Group 2014-02 2013-12-04 /pmc/articles/PMC3904553/ /pubmed/24060819 http://dx.doi.org/10.1038/clpt.2013.177 Text en Copyright © 2014 American Society of Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | State of the Art Selker, H P Oye, K A Eichler, H-G Stockbridge, N L Mehta, C R Kaitin, K I McElwee, N E Honig, P K Erban, J K D'Agostino, R B A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials |
title | A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials |
title_full | A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials |
title_fullStr | A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials |
title_full_unstemmed | A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials |
title_short | A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials |
title_sort | proposal for integrated efficacy-to-effectiveness (e2e) clinical trials |
topic | State of the Art |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904553/ https://www.ncbi.nlm.nih.gov/pubmed/24060819 http://dx.doi.org/10.1038/clpt.2013.177 |
work_keys_str_mv | AT selkerhp aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT oyeka aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT eichlerhg aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT stockbridgenl aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT mehtacr aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT kaitinki aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT mcelweene aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT honigpk aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT erbanjk aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT dagostinorb aproposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT selkerhp proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT oyeka proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT eichlerhg proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT stockbridgenl proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT mehtacr proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT kaitinki proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT mcelweene proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT honigpk proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT erbanjk proposalforintegratedefficacytoeffectivenesse2eclinicaltrials AT dagostinorb proposalforintegratedefficacytoeffectivenesse2eclinicaltrials |